trending Market Intelligence /marketintelligence/en/news-insights/trending/vc0td5ecu5ga3nrgufsklq2 content esgSubNav
In This List

Alnylam looks at value-based contracts; medical marijuana stocks on a high


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Alnylam looks at value-based contracts; medical marijuana stocks on a high

Here are the editors' top picks for the week ended June 15.

Alnylam CEO: Six-digit price, value-based contracts in sight for new therapy

Alnylam Pharmaceuticals Inc. is poised for drug launches through 2021 and is actively looking at value-based agreements for its cell therapies, said CEO and director John Maraganore.

Medical marijuana stocks on a high as legislation could pave way for greater use

The medical marijuana industry has seen rapid growth as the prospects for further legalization improve and investors fund innovators looking at expanding the use of cannabis, with the market expected to more than double in size by 2022.

US Senate panel advances bill to speed lawsuits combating big pharma gaming

A bill aimed at combating anti-competitive practices used by brand-name drug manufacturers to impede generic rivals was advanced to the Senate floor by the chamber's Judiciary Committee.

FDA rolls out guidelines to lower drug costs, preserve antibiotic market

U.S. Food and Drug Administration Commissioner Scott Gottlieb issued a set of three new guidelines for drugmakers aimed at supporting better price negotiations, driving competition and securing reimbursement.

Gene therapy group gears up for education campaign as CRISPR anxiety grows

A recent study linking gene-editing tool CRISPR to cancer comes just as industry groups ramp up efforts to reach consumers and physicians.

NIH outlines $500M spending plan for HEAL projects to combat opioid crisis

The National Institutes of Health outlined how it plans to spend the $500 million Congress allotted to address the opioid crisis — projects that include vaccines to prevent fentanyl overdoses and longer-acting formulations of drugs to treat addiction.

HHS chief says drugmakers discussing price cuts, but backs off Trump's promise

A number of drugmakers have been in discussions with the Health and Human Services Department about lowering their prices, Secretary Alex Azar told lawmakers on Capitol Hill. But he was unable to provide evidence those companies were ready to commit.

Capitol Checkup: Insulin price deal; right-to-try threats; flu deadly for kids

If the Trump administration struck a deal to lower insulin prices, the largest makers of those products were unaware; drug companies may be facing social media firestorms now that the Right To Try Act is law; and 172 U.S. children died of the flu.

WHO: 1 new Ebola case reported; treatments on the ground in DRC

Four out of five experimental Ebola treatments are on the ground in the Democratic Republic of the Congo and being administered under compassionate use, World Health Organization officials said.